Last Updated on July 8, 2021 by The Health Master
The National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of antifungal drug Amphotericin B (emulsion) injection 50mg at Rs. 3,136.81 per pack excluding GST vide office memorandum dated 05-07-2021. It is on par with ceiling price of amphotericin B (lipid) powder for injection 50mg.
The matter to relating to fixation of ceiling price of amphotericin B (emulsion) injection 50mg was deliberated upon in 89th meeting of the drug price regulation authority held on June 28, 2021 in which it was decided that the ceiling price as applicable for amphotericin B (lipid) powder for injection 50mg is also applicable for amphotericin B (emulsion) injection having the same dosage form and strength.
The ceiling price of amphotericin B (lipid) powder for injection 50mg stood at Rs. 3,136.81 per pack excluding GST. The NPPA on August 14, 2019 passed an order to fix the retail prices of formulations of ‘Amphotericin B’ under the Drugs (Prices Control) Order, 2013.
The ceiling price of another formulation of the antifungal drug i.e. amphotericin B liposomal powder for injection 50mg was fixed at Rs. 7,306.60 per pack excluding GST.
Earlier, an expert committee of NPPA in its 33rd meeting on June 21, 2021 also deliberated on the issue pertaining to fixation of ceiling price of amphotericin B (emulsion) injection 50mg.
The committee noted that three variants of amphotericin B powder for injection i.e conventional, lipid and liposomal are scheduled formulations under DPCO 2013 and the ceiling price is fixed.
Hence, it decided that a clarification be obtained from Central Drugs Standard Control Organisation (CDSCO) as to whether emulsion form of amphotericin B has major difference from lipid form to consider a separate price for it or ceiling price notified for amphotericin B (lipid) may also be extended to amphotericin B (emulsion).
Amphotericin B is currently sold by Abbott, Bharat Serums, Cipla, Sun Pharma and Viatris. Five drug makers including Alembic, Emcure and Natco received approval from the Drugs Controller General of India (DCGI) to manufacture the antifungal drug.